PharmaCyte Biotech Inc (PMCB)

[$Pistol Pete$]

Cell-in-a-Box™ has countless potential indications that it could address, but Nuvilex is first focused on using it as part of a treatment for advanced, inoperable pancreatic cancer, a leading cause of deaths from cancer worldwide. In the U.S. alone, about 45,000 new cases have been predicted by the American Cancer Society to be diagnosed in 2013 with about 38,000 deaths expected from the disease. In 1996, Ely Lilly’s (NYSE:LLY) drug Gemzar® (gemcitabine) became the first treatment for advanced, inoperable pancreatic cancer approved by the US FDA. To this day, it is still the only single-agent drug approved for the indication with the other two approved therapies being drug combinations that include gemcitabine.

Is Cell-in-a-Box™ will be the next one?

$NVLX

Pistol Pete!